NSABP Objects to “Closed Process” For Review Of P-4 Breast Cancer Chemoprevention Trial.
NCI Barred PI Wolmark And Its Own Prevention Staff From Ad Hod Meeting.
NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.
Paul Goss, Patricia Ganz Discuss Breast Cancer Prevention Trials.
Aranesp Study Finds No Difference In Survival Or Progression In Small-Cell Lung Cancer.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - The Galleri MCD vote: What FDA asked its advisors to ignore
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
